Background {#Sec1}
==========

Multiple stakeholders, including regulatory authorities, clinicians, payers (commissioners) and health technology assessors, are involved in market introduction and management pathways for health technologies. From the perspective of these stakeholders, monitoring of blood glucose (BG) in insulin-dependent diabetes has strong global support from clinical societies \[[@CR1]--[@CR6]\]. The American Diabetes Association guidelines specify that "major clinical trials of insulin-treated patients that demonstrated the benefits of intensive glycemic control on diabetes complications have included self-monitoring of blood glucose (SMBG) as part of multifactorial interventions, suggesting that SMBG is a component of effective therapy" \[[@CR1]\]. Regulatory authorities have approved the use of blood glucose meters for use with insulin products and have outlined instructions for the measurement of BG \[[@CR7]\]. Health technology assessments, although rarely focused on SMBG in insulin-dependent diabetes, have also been in general supportive of BG monitoring \[[@CR8],[@CR9]\]. Lack of understanding of the role of BG monitoring in the safe and effective use of insulin leads to restrictions or no coverage of SMBG in some developing countries, while reimbursement for insulin treatment is provided \[[@CR10]\]. According to Czupryniak et al. \[[@CR11]\], access to SMBG is limited especially in Central and Eastern European countries. In a survey conducted in 47 countries by the International Diabetes Federation, existing limitations for access to SMBG were also confirmed \[[@CR12]\]. Limitations usually do not have rational ground and can mainly be explained by the absence of a consistent reimbursement system. Another potential reason for restrictions of SMBG is the lack of randomized controlled trials (RCTs) for comparing the management of insulin-dependent diabetes with and without SMBG. RCTs are considered as a "gold standard" for assessment of safety and efficacy of health care interventions \[[@CR13]\], although their role in assessment of effectiveness of SMBG as stand-alone technology can be reasonably questioned. The role of SMBG in insulin-dependent diabetes has not been studied in RCTs and does not require validation in comparative studies, as it would be considered unethical to allocate patients to insulin without the ability to determine and adjust dose based on BG measurements. Another contributing factor to complexity of assessment of efficacy of SMBG is that is it a diagnostic measure, not a treatment intervention.

SMBG and the use of insulin are ultimately linked together for an effective and safe therapy. Regulatory approval of insulin has been established in phase III clinical studies \[[@CR14]\]. Because BG is an essential component of these foundational studies of the safety and efficacy of insulin treatment, it provides additional arguments for the use of SMBG, and thus confirms the co-dependent nature of SMBG and insulin treatment. Therefore, it is necessary to consider them jointly in evidence evaluations and reimbursement decision making, and BG monitoring should be mentioned as a part of the intervention in the studies on insulin analogs.

In a preliminary review of phase III clinical studies of insulin analogs, it was found that in only 12 of the 57 study synopses analyzed, dose adjustments were made according to BG measurements \[[@CR7]\]. In addition, full text reports were not available for review in most of the studies. Our study aimed to explore this area further, and we hypothesized that phase III registration studies of commonly used insulin analogs (biphasic insulin aspart, insulin aspart, insulin glulisine, insulin lispro and insulin lispro mix) include BG monitoring and consequent regular dose adjustment as an essential element of the research protocol. The resulting impact on the treatment outcomes is thought to be a joint effect of the co-dependent technologies.

Methods {#Sec2}
=======

A systematic literature review was performed in multiple steps. First, a systematic search for phase III clinical studies was performed on the manufacturers' websites (Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A.). The rapid-acting insulin analogs included insulin aspart (NovoRapid®), insulin glulisine (Apidra®) and insulin lispro (Humalog®). Pre-mixed insulin analogs included biphasic insulin aspart (Novo Mix®) and insulin lispro mix (Humalog Mix®). All searches were conducted in December 2013. Second, Clinical Study Reports were requested from the European Medicines Agency (EMA), according to Regulation (EC) No 1049/2001. Third, an additional search for full-text publications was performed in Medline and Medline In-Process bibliographic databases using the clinicaltrials.gov identification number (clinical trial ID) or the manufacturer's study ID. If no full-text publication was identified in the bibliographic databases, a search was performed in the registry of clinical studies clinicaltrial.gov. Finally, a study synopsis or summary was retrieved from the manufacturers' websites. Only prospective phase III clinical trials of insulin analogs that reported clinical outcomes were included, as insulin analogs (in comparison with human insulin) are more recently available and have followed the most recent regulatory procedures.

Data collected included country of origin, design of the study, sample size, mean age, type of diabetes, duration of diabetes, proportion of males, use of insulin before enrollment into study, target glycated hemoglobin (HbA1c) in the inclusion and exclusion criteria, mean HbA1c, use and purpose of BG measurement, method of insulin dose adjustment, structuration of SMBG, provision of education/training for SMBG, and monitoring of compliance in SMBG. The data were extracted by one reviewer and validated by a second reviewer. Any disagreements were resolved by consensus. No statistical hypothesis was tested. The main outcomes included frequency of use of BG monitoring and use of BG monitoring for insulin dose adjustment. Summary statistics were provided using SPSS version 20 (IBM Corp., Armonk, New York, USA). Study did not require ethical approval, as it did not include any patient's data.

Results {#Sec3}
=======

Clinical studies search {#Sec4}
-----------------------

Altogether 46 phase III clinical trials were identified in the manufacturers' websites. One retrospective study (NCT00410033) was excluded from analysis, as it did not meet inclusion criteria. The database search in Medline provided 27 full-text articles, one of which was identified as a duplicate \[[@CR15]\] and five as redundant publications \[[@CR16]--[@CR20]\]. All five redundant publications were considered less informative than the main published phase III clinical study in question. EMA provided eight out of the 45 requested extracts of Clinical Study Reports of the phase III insulin analog studies. The majority of the Clinical Study Reports were not held by EMA. The analog reports which were provided consisted of the following: insulin glulisine (*n* = 1), biphasic insulin aspart (*n* = 3) and insulin lispro (*n* = 4). For three studies, both the Clinical Study Reports and full-text publications were available, but for five studies, only the Clinical Study Report was available. A detailed description of the selection process as adapted from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework \[[@CR21]\] is presented in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Selection of phase III trials and subsequent full-text publications (adapted from PRISMA \[[@CR21]\])

Description of included studies {#Sec5}
-------------------------------

The characteristics of the included studies are described in Table [1](#Tab1){ref-type="table"}. Of the identified phase III studies, 62 % (*n* = 28) were rapid-acting insulin analog studies and 38 % (*n* = 17) were pre-mixed insulin analog studies. Of the rapid-acting analogs, 29 % (*n* = 8) were insulin aspart, 57 % (*n* = 16) were insulin glulisine and 14 % (*n* = 4) were insulin lispro. Of the pre-mixed insulin analog studies, 71 % (*n* = 12) were biphasic insulin aspart studies and 29 % (*n* = 5) insulin lispro mix studies.Table 1Characteristics of the included study reportsInsulin analog typeInsulin analogClinical trial IDEMA reportFirst author of full-text articleYearDesignSample sizeMean age of totalPopulationDM typeMean duration of DM in yearsMale (%)Mean HbA1c (%) at baselineRapid-actingInsulin aspart (Novo Rapid)NCT01388361NMathieu \[[@CR29]\]2014RCT41361.3AII11.8647.3NCT00097071NWeinzimer \[[@CR30]\]2008RCT29913.1CI6.1488.1NCT00604656NNone2004RCT24140.2AI13.6667.8NCT00071448NNone2006RCT37811.6CI4.6528.3NCT01486940NHermansen \[[@CR27]\]2004RCT64439.1AI15.2638.4NCT00065130NPettitt \[[@CR31]\]2007RCT2730.7AGDM--05.2NCT00832182NNone \[[@CR32]\]\*2002Cohort75--AI------NCT01707134NHome \[[@CR33]\]2006RCT75338.8AI15.258--Insulin glulisine (Apidra)NCT00467376NNone2009RCT484--AI, II10.3--8.6NCT00115570NNone2009RCT57212.5CI------NCT00290979NNone2006RCT267--AI------NCT00290927NNone2005RCT393--AII------NCT00135057YBergenstal \[[@CR34]\]2008RCT27055.1AII13.0448.2NCT00135096NRatner \[[@CR35]\]2011RCT71653.8AII14.0448.4NCT00174668NNone2008RCT310--AII------NCT00546702NNone2005CS140--AI------NCT00545337NNone2007CS6034.7AI12.745--NCT00174642NNone2009RCT46458.5AII--459.1NCT00272012NNone2007RCT393--AII------NCT00135941NTesta \[[@CR36]\]2012RCT38854.0AI, II16.1477.8NCT00135083NDavidson \[[@CR37]\]2011RCT343--AII--5--NCT00272064NDel Prato \[[@CR38]\]2012RCT24158.3AII10.9528.9NCT00271284NRenard \[[@CR39]\]2011RCT13546.8AI18617.1NCT00397553NNone2009CS10435.0AI25.3--8.8Insulin lispro (Humalog)F3Z-MC-IOAEYNone1994RCT9824.4MI0.261--F3Z-MC-IOAFYNone1994RCT37756.1AII7.856--F3Z-MC-IOAGYNone1993RCT103733.4MI12.1588.5F3Z-MC-IOAHYNone1993RCT77758.6AII12.6548.9Pre-mixedBiphasic insulin aspart (Novo Mix)NCT00476437NNone2008RCT8162.3AII18.3547.8NCT00318786NKadowaki \[[@CR40]\]2010RCT28962.5AII15.7598.5NCT00313001NNone2007RCT37252.6AII--4810.2NCT00184574NCucinotta \[[@CR41]\]2009RCT60360.5AII--448.9NCT00097877NBergenstal \[[@CR42]\]2009RCT37252.6AII--4810.2NCT00184600NHolman \[[@CR18]\]2009RCT70861.7AII9648.5NCT00097279YRaskin \[[@CR43]\]2007RCT23053.8AII8.8428.1NCT00564668NNone2005RCT12662.2AII16.4627.2NCT00612599NParkner \[[@CR44]\]2010RCT7560.4AII11.7707.5NCT00617565YNone2004RCT21955.8AI, II11.1568.8NCT01467375NNone \[[@CR45]\]\*2005CS8965.1AII15.2658.1NCT01467323YBoehm \[[@CR46]\]2002RCT29454.0AI, II15.3588.3Insulin lispro mix (Humalog Mix)NCT00191581NGao \[[@CR47]\]2008RCT12055.7AI, II11.4408.1NCT00551356NNone2003RCT5350.4AII6.557--F3Z-JE-IOMONNone2003RCT21555.9AI, II15.058--F3Z-MC-IONANNone2006RCT10652.4AI, II10.452--NCT00036504NNone2007RCT10554.9AII8.9628.6*Abbreviations*: *EMA* European Medicines Agency; design: *RCT* randomized control trial, *CS* case series study; population: *A* adult, *C* child and/or adolescent, *M* mixed*DM* diabetes mellitus; type: I diabetes mellitus type I, II--diabetes mellitus type II, GDM-gestational diabetes; HbA1c-glycated hemoglobin\*Unpublished study. Reference provides additional information

The majority (*n* = 40, 89 %) of the included studies were RCTs. In total 60 % (*n* = 27) were single-country studies conducted in USA (*n* = 9, 20 %), Japan (*n* = 5, 11 %), China (*n* = 3, 7 %), Russia (*n* = 2, 5 %), and 1 (*n* = 1, 2 %) each in Germany, Denmark, Italy, France, Mexico, the Netherlands and Ukraine. There were 29 % (*n* = 13) of the studies conducted in multiple countries; the location was not specified in 14 % (*n* = 6) of the studies. The median number of patients in the studies was 280 (interquartile range 113--403).

Type 1 diabetes mellitus (DM) patients were included in 31 % (*n* = 14) and type 2 DM patients in 51 % (*n* = 23) of the studies. A mixed population consisting of patients with both type 1 and 2 DM was identified in 16 % (*n* = 7) of the studies. One study included patients with gestational DM only.

In 89 % (*n* = 40) of the studies, only adults were included, and in 7 % (*n* = 3) only children and/or adolescents were included. In two (4 %) studies, the patient population was mixed where both adults and children were included. Mean age of patients in all studies was 48.3 (standard deviation \[SD\] 14.6) years. Males constituted on average 53 % of all study participants. The mean duration of diabetes prior to enrolment was 12.2 (SD 4.6) years and insulin therapy had been initiated prior to enrolment in 78 % of the studies. Patients had not received insulin therapy prior to enrolment in 13 % of the studies. The mean level of HbA1c at baseline was 8.3 % (SD 0.9 %).

BG monitoring in the included studies {#Sec6}
-------------------------------------

### BG monitoring {#Sec7}

A summary of the results is presented in Table [2](#Tab2){ref-type="table"}. Regular monitoring of BG was reported in 100 % (*n* = 45) of the studies as shown in Fig. [2](#Fig2){ref-type="fig"}.Table 2Review of phase III insulin analog clinical trialsRapid-acting insulin analogsPre-mixed insulin analogsTotalInsulin aspart (Novo Rapid)Insulin glulisine (Apidra)Insulin lispro (Humalog)Biphasic insulin aspart (Novo Mix)Insulin lispro mix (Humalog Mix)Rapid-actingPre-mixAll insulin analog studiesTotal number of trials (n)8164125281745*All insulin analog studies (n = 45)*Proportion of trials reporting BG measurement (%)100 %100 %100 %100 %100 %100 %100 %100 %*Reported BG by SMBG, laboratory or both (n = 45)*Reported BG measurement by SMBG only (%)100 %82 %75 %83 %80 %86 %82 %84 %Reported BG measurement by laboratory measurement only (%)0 %12 %0 %0 %20 %7 %6 %7 %Reported BG by both SMBG and laboratory measurements (%)0 %6 %25 %17 %0 %7 %12 %9 %*Reported regular insulin dose adjustments (using BG measurements, n = 45)*Reported dose adjustments according to BG measurement (%)87.5 %100 %100 %91.6 %60.0 %96.4 %82.4 %91.1 %*Reported regular dose adjustments by patient or physician (using BG measurements, n = 45)*Reported dose adjustments by patient (%)25.0 %43.7%0 %41.7 %0 %32.1 %29.4 %31.1 %Reported dose adjustments by physician (%)37.5 %25.0 %100 %33.3 %40.0 %39.3 %35.3 %37.8 %Reported dose adjustments by patient and physician (%)0 %6.3 %0 %8.3 %0 %3.6 %5.9 %4.4 %Reported dose adjustments, not specified by patient or physician (%)25.0 %25.0 %0 %8.3 %20.0 %21.4 %11.8 %17.8 %*Reported regular dose adjustments using SMBG measurements (n = 42)*Patient self-adjustments using SMBG values (%)25.0 %50 %0 %41.7 %0 %34.6 %31.3 %33.3 %Physician adjustments using SMBG values (%)37.5 %28.6 %75 %33.3 %50 %38.5 %37.5 %38.1 %Patient and physician adjustments using SMBG values (%)0 %7.1 %0 %8.3 %0 %3.8 %6.3 %4.8 %Dose adjustments using SMBG mentioned but not specified whether by patient or physician (%)25.0 %7.1 %0 %0 %25 %11.5 %6.3 %9.5 %Fig. 2Proportion of phase III clinical trials that reported regular BG monitoring per insulin analog type

Insulin doses were reportedly adjusted based on regular BG measurements in 91 % of phase III studies (Fig. [3](#Fig3){ref-type="fig"}). In total 31.1 % the studies were with patients making insulin dose adjustments using BG values. Physician-adjusted insulin dosing using BG values was reported in 37.8 % of the clinical studies that reported BG monitoring. In 4.4 % of the studies dose adjustment was reported by both patients and physicians. In 18 % of the studies, dose adjustment based on BG values was performed, but it was not specified by whom.Fig. 3Proportion of phase III trials reporting insulin dose adjustments

### SMBG monitoring {#Sec8}

SMBG was reported in 93 % (*n* = 42) of the phase III clinical studies. The proportions of studies using either rapid-acting or pre-mixed insulin analogs were similar in terms of those reporting SMBG. SMBG was used as the only means of BG monitoring in 84 % (*n* = 38) of the studies. Monitoring of BG using only laboratory means was reported in 7 % (*n* = 3) of the studies. Both laboratory and SMBG measurements were reported in 9 % (*n* = 4) of the studies.

With regard to insulin dose adjustments based on SMBG, 33.3 % (*n* = 14) of the phase III clinical studies reported that patients self-adjusted insulin doses based on SMBG results. The proportion of these studies using either rapid-acting (*n* = 9, 34.6 %) or pre-mixed insulin (*n* = 5, 31.3 %) was the same. Adjustment of insulin doses by physicians based on SMBG values were reported in 38.1 % (*n* = 16) of the studies. Dose adjustment by physicians based on SMBG was similar in the pre-mixed (*n* = 6, 37.5 %) and the rapid-acting insulin analog (*n* = 10, 38.5 %) studies. In two studies (4.8 %) SMBG-based dose adjustments were reported both by patients and physicians. In four (9.5 %) studies that reported dose adjustments based on SMBG, it could not be determined whether the dose adjustments were carried out by physician or patient.

Daily frequencies of SMBG measurement were reported in 83 % (*n* = 35) of the studies that reported the use of SMBG. In general, the daily frequencies varied between one to nine tests.

Training, education and provision of instructions for the proper use of SMBG were reported in 55 % (*n* = 23) of the phase III studies where SMBG was reported. Monitoring the proper use of SMBG was reported in 64 % (*n* = 27) of the studies that reported SMBG measurements. The monitoring was frequently done by regular checks via telephone and by inspecting patient diaries.

Discussion {#Sec9}
==========

To our knowledge, the present study is the first to systematically assess the role of SMBG in phase III clinical studies. It confirms the role of BG measurement as an essential component of safe and effective insulin therapy. We found that in 100 % of phase-III clinical studies of analog insulins, BG monitoring was regularly used. SMBG was the most prevalent monitoring option and was reported in 93 % of the studies.

We also found that in the majority of the studies insulin therapy was regularly adjusted based on the BG measurements. Therefore, the safety and efficacy of insulin use requires guidance for patients in the use of BG measurements and the corresponding dose adjustments. Of the studies reporting BG use, 31 % included insulin dose self-adjustment by patients, 38 % with dose adjustment by physicians, 4 % with dose adjustment by both patients and physicians and finally 18 % in which dose adjustment was performed, but it was not reported by whom. For the other studies that did not explicitly mention insulin dose adjustment based on BG measurement, we cannot rule out that dose adjustment did not occur. However, all these studies were unpublished and no Clinical Study Reports were available. If the analysis is limited only to the studies for which either full text publication or the Clinical Study Report is available, then insulin dose adjustment based on BG measurements would be in 100 % of the studies, both for rapid-acting and pre-mixed insulins.

Our analysis also showed that only 55 % of the examined studies report that training, education or provision of instructions about the use of SMBG took place. We believe that this relatively low value reflects incomplete reporting in the studies, rather than a lack of provision of training. Studies have demonstrated that structured testing can enhance the value of SMBG \[[@CR22]--[@CR24]\]. Structured testing means measuring BG at specific times or in relation to activities in order to best evaluate the effect of therapy, diet and physical activity on the BG level \[[@CR25]\]. In a review of the European Public Assessment Reports for insulin analogs, it was revealed that unspecific and unclear recommendations for BG monitoring is occasionally provided \[[@CR7]\]. To ensure safe and effective use of insulin, manufacturers should be encouraged to provide clearer recommendations for patients and medical professionals.

This study contributes to the understanding of the essential role of BG monitoring in insulin-dependent diabetes. Insulin is safe and effective if used only in combination with regular BG monitoring. This is true for both rapid-acting and pre-mixed insulins, the latter typically used in conventional insulin therapy. The value of BG monitoring is for providing essential information for making therapeutic choices, either by the patient or the physician. And SMBG is only helpful, if it results in therapeutic consequences. To achieve that SMBG shall be placed in the center of the disease management for diabetic patients, including appropriate training of structured testing, as mentioned above. The use of both SMBG and insulin is funded in the majority of developed countries by payers. In some developing countries, reimbursement is not available for BG meters and strips, while coverage for insulin treatment is provided. The lack of affordability or reimbursement limitations of SMBG may impair adherence to the recommended BG test frequencies and result in not achieving the required level of efficacy and safety of insulin, which could ultimately lead to adverse outcomes for the patients and an increase in cost to the health care system due to ineffective management of diabetes.

Data on the impact of non-provision of SMBG on insulin-dependent patients are limited, although some emerging evidence shows a potential serious risk of a reduction of insulin effectiveness. In China, where SMBG is not reimbursed, a study in 2011 with 10,418 patients with diabetes revealed that a high proportion of insulin-dependent patients do not have a meter at home to perform SMBG (51.6 % of patients on intensive insulin therapy, 46.6 % on conventional insulin therapy and 39.9 % on basal-supported oral therapy) \[[@CR26]\]. In all three of these clinical groups, the average level of HbA1c was higher in patients who did not have access to a SMBG meter (e.g., HbA1c 8.1 % with SMBG vs HbA1c 9.3 % without SMBG among patients on intensive insulin therapy). In another study from India (*n* = 2250) using a similar study methodology as in the study in China of accessibility to SMBG, it was found that 41.5 % of patients on intensive insulin therapy, 54.3 % on conventional insulin therapy and 44.6 % on basal-supported oral therapy did not have a meter at home to perform SMBG \[[@CR27]\]. The level of glycemic control was lower in patients who did not perform SMBG. In a study performed in Italy, it was demonstrated that patients using SMBG had a reduced risk of diabetes-related hospitalizations and consequently a lower overall total annual cost per patient \[[@CR28]\]. Total annual cost was €3060 in the group of no SMBG users vs. €2738 in the group of patients using SMBG, which was mainly explained by statistically significant reduction of diabetes-related hospitalizations.

Non-coverage of SMBG in some developing countries is a good example of 'silo budgeting' to overcome, when different payers are responsible for provision of drugs and diagnostics/medical aids. Being disconnected, the decision-making and financial flows for drugs and medical aids may lead to a break in provision of strongly co-dependent technologies, such as with insulin and SMBG. Many countries have taken action to overcome this hurdle, which requires a holistic view of the outcomes and costs in health care from the perspective of the entire society and not just from the perspective of a single payer.

Our study has some limitations. First, our search for full text articles was limited to one bibliographic database and was performed using a clinical trial identifier, which may have led to the loss of some relevant publications. Nevertheless, we were able to answer the primary question about the use of BG monitoring from the studies examined using a combination of sources, including full text articles, study synopses and EMA reports. The non-inclusion of existing full text reports may have potentially led to underreporting of dose adjustment, based on SMBG, and to the provision for training to patients on the use of SMBG. Second, our study scope was only on registered phase III studies, which was used as a foundation for insulin analog safety and efficacy claims and consequent regulatory approval, and did not include other pre- and post-marketing studies.

Conclusions {#Sec10}
===========

To conclude, the findings from this review endorse the crucial role of BG measurement in general and of SMBG specifically as a co-dependent intervention component of insulin treatment. The majority of phase III registration studies reported on the use of BG measurements for establishing safe and efficacious administration of insulin. The indispensable role of SMBG in treatment for insulin-dependent patients should receive the attention of health care payers in order to consistently assess and reimburse SMBG along with insulins to ensure the safety and effectiveness of insulin treatment.
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